Signature Wealth Management Partners LLC Purchases 232,426 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Signature Wealth Management Partners LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 232,426 shares of the company’s stock, valued at approximately $4,681,000. Amneal Pharmaceuticals accounts for 2.0% of Signature Wealth Management Partners LLC’s portfolio, making the stock its 12th largest position. Signature Wealth Management Partners LLC owned about 0.07% of Amneal Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its position in shares of Amneal Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after purchasing an additional 81,546 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Amneal Pharmaceuticals by 72.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after purchasing an additional 1,069,400 shares in the last quarter. Congress Asset Management Co. increased its position in shares of Amneal Pharmaceuticals by 94.7% during the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock worth $30,701,000 after purchasing an additional 741,577 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at $17,573,000. Finally, Principal Financial Group Inc. raised its stake in Amneal Pharmaceuticals by 527.9% in the 1st quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock valued at $12,089,000 after purchasing an additional 817,652 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AMRX shares. UBS Group reaffirmed a “buy” rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Leerink Partners started coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 price target on the stock. Oppenheimer began coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price target on the stock. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Finally, Zacks Research lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Amneal Pharmaceuticals Stock Up 1.8%

Shares of NASDAQ:AMRX opened at $20.20 on Thursday. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The business has a fifty day moving average of $18.68 and a two-hundred day moving average of $16.36. The stock has a market cap of $6.45 billion, a P/E ratio of 41.22, a PEG ratio of 2.33 and a beta of 1.22. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.99 and a 52-week high of $21.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.24 by $0.06. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.95 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 146,403 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares in the company, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the sale, the director owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is owned by company insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.